Overall market sentiment has been neutral on IGM Biosciences Inc (IGMS) stock lately. IGMS receives a Neutral rating from InvestorsObserver Stock Sentiment Indicator.
IGM Biosciences Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on IGMS!
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With IGMS Stock Today?
IGM Biosciences Inc (IGMS) stock is trading at $9.17 as of 2:25 PM on Monday, Mar 25, a drop of -$1.12, or -10.88% from the previous closing price of $10.29. The stock has traded between $9.14 and $10.57 so far today. Volume today is light. So far 175,664 shares have traded compared to average volume of 308,689 shares.
To see InvestorsObserver's Sentiment Score for IGM Biosciences Inc click here.
More About IGM Biosciences Inc
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.
Click Here to get the full Stock Report for IGM Biosciences Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
